Mizuho analyst Graig Suvannavejh raised the firm’s price target on Apellis (APLS) to $41 from $20 and keeps a Neutral rating on the shares. The firm cites the announced acquisition offer for the target increase. It views Biogen’s offer as “highly compelling” and does not expect another bidder to emerge.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on APLS:
- Apellis downgraded to Neutral from Buy at Roth Capital
- Disney upgraded, Nike downgraded: Wall Street’s top analyst calls
- Biogen price target raised to $275 from $250 at Oppenheimer
- Apellis downgraded to Neutral from Buy at H.C. Wainwright
- Apellis: Hold Rating as Biogen Takeout Caps Upside and CVR Payouts Look Unlikely Under Conservative Syfovre Outlook